Business context and reporting period
Filing identity: The supplied filing is Sema4 Holdings Corp. (Nasdaq: SMFR), not GeneDx Holdings Corp. The filing identifies GeneDx as an acquired subsidiary. Verify that this is the intended filing.
This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2022. Sema4 provides genomic diagnostic and information services. Results include GeneDx from its April 29, 2022 acquisition date; the prior-year comparison does not include GeneDx on the same basis.
Key financial metrics
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $83.2 million | $43.2 million | $173.3 million | $154.4 million |
| Gross profit (loss) | $13.5 million | $(8.3) million | $(10.4) million | $(13.8) million |
| Gross margin | 16% | (19)% | (6)% | (9)% |
| Operating loss | $(90.8) million | $(88.3) million | $(342.8) million | $(330.4) million |
| Net income (loss) | $(77.6) million | $32.7 million | $(240.2) million | $(205.2) million |
| Adjusted EBITDA (non-GAAP) | $(70.0) million | $(64.5) million | $(244.0) million | $(126.6) million |
Q3 diagnostic revenue rose 97%, primarily reflecting $45.6 million of GeneDx revenue; total revenue increased 93%. Nine-month revenue rose 12%, including $71.7 million from GeneDx, partly offset by a $30.1 million prior-period revenue reversal related mainly to payor reserves and lower reimbursement, and lower COVID-19 testing revenue.
Cash and cash equivalents were $191.4 million at September 30, versus $400.6 million at December 31, 2021; restricted cash was an additional $14.4 million. Nine-month operating cash use was $254.5 million, investing cash use $138.5 million, and financing cash provided $197.3 million. The investing outflow included $127.0 million, net of acquired cash, for GeneDx.
Total liabilities were $267.7 million. Long-term debt was $11.0 million, including $10.7 million non-current; the company also had $67.8 million of lease liabilities. A $125 million revolving credit facility was undrawn. Management said cash and cash equivalents were expected to fund operations for at least 12 months from the filing date.
Material changes, outlook and risks
- Strategic exits: In August, the company announced plans to discontinue somatic tumor testing and close its Branford lab by December 31, 2022. In November, after quarter-end, it announced plans to exit reproductive and women’s health testing, stop accepting samples December 14, 2022, and complete the exit by the end of Q1 2023. It expects material future cash and non-cash charges; the impact was not yet estimable. Management cited reimbursement shifts, declining prices, competition and cost structure, and said it could not find a buyer for the business.
- Restructuring: The planned somatic-testing exit included eliminating approximately 250 positions, about 13% of the workforce. The later women’s-health exit is expected to eliminate approximately 500 positions, about 32.5% of the workforce, and close the Stamford lab. The company cautioned that actual restructuring costs and savings may differ from estimates.
- Payor exposure: A third-party payor alleges overpayments and has indicated it may seek recovery. The company disputes the allegations and is seeking resolution. It recorded $39.8 million of combined liabilities for this and other potential payor settlements at September 30; the second-quarter revenue adjustment was $30.1 million. A billing-claims and compliance review was initiated in Q3.
- Unusual earnings items: Q3 included $13.0 million of gains from fair-value changes in warrant and earn-out liabilities. Nine-month results included $54.4 million of such gains and a $49.1 million income-tax benefit, largely associated with deferred-tax accounting following the GeneDx acquisition. These items do not represent recurring operating performance.
- Contingent acquisition payments: Up to $150 million may be payable to OPKO based on GeneDx 2022 and 2023 revenue milestones. The recorded fair value was $24.4 million at September 30; milestone payments may be settled in cash, shares, or both.
- Other risks: The company reported a shareholder class action filed in September 2022 and said it considers the claims without merit. It also disclosed that disclosure controls were ineffective because previously identified material weaknesses in internal financial reporting had not been fully remediated. Management stated the financial statements were fairly presented.
- Guidance: The filing provides no clear quantified revenue, earnings or cash-flow guidance. Management expects cost savings and gross-margin benefits from the somatic-testing exit, but cautions that the benefits and timing are uncertain.
Important facts for investors to verify
- Confirm the intended issuer: the filing is for Sema4 Holdings Corp., although the request metadata names GeneDx Holdings Corp.
- Track cash burn against the stated 12-month liquidity outlook, and confirm whether additional financing or cost reductions become necessary.
- Monitor the payor dispute, the $39.8 million reserve, potential recoupments and any effect on contracted reimbursement rates.
- Assess execution, costs and realized savings from the announced business exits, facility closures and workforce reductions.
- Verify GeneDx revenue-milestone performance and the resulting potential payment to OPKO, including any cash-versus-share settlement choice.
- Follow remediation of material weaknesses and developments in the shareholder litigation.